Although Akt has been recently proposed as a therapeutic target for AD-associated memory impairments (Griffin et al., 2005), different results have been obtained about the Akt activation across brain structures of human AD (Rickle et al., 2004; Petersen et al., 2007; Lachén-Montes et al., 2016). This evidence concerns the gene AKT1 and memory impairment.